Magellan Rx Management, the PBM division of Magellan Health, Inc., on June 4 announced its launch of an oncology biosimilars program, preparing its health plan customers for the expected market entry of biosimilars for three cancer-fighting drugs — Herceptin, Rituxan and Avastin — later this year.
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits
- Headlines in the News
- Abstract, Medicare and Medicaid